Measures and markers in Amyotrophic Lateral Sclerosis

SummaryAmyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized by loss of spinal and cortical motor neurons, leading to progressive weakness and ultimately, death. Clinically, there appears to be an anatomic focus at disease onset, from which the disease then spreads. Because the focus of initial symptoms and the subsequent direction of spread can vary from patient to patient, disease monitoring is difficult, especially in a clinical trial, in which outcome measures must be identical and able to capture progression of all types. Thus, the search for markers of disease progression is especially important in ALS. Many approaches have been taken, from voluntary strength assessment and functional rating scales to physiological and pathological sampling of affected portions of nervous system. No proposed marker has been demonstrated to meet the desired criteria of biological meaning, sensitivity to disease progression, clear relationship to overall prognosis and survival, and ease of measurement. However, progress is being made in all of these regards.

[1]  A. Eisen,et al.  Cortical Excitability in Amyotrophic Lateral Sclerosis: A Clue to Pathogenesis , 1993, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[2]  J R Daube,et al.  Estimating the Number of Motor Units in a Muscle , 1995, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[3]  R. Tarducci,et al.  Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis , 2001, Neuroradiology.

[4]  Stefano Tamburin,et al.  Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis , 2002, Journal of Neurology.

[5]  M A Horsfield,et al.  Diffusion tensor MRI assesses corticospinal tract damage in ALS , 1999, Neurology.

[6]  Lin Jin,et al.  Aberrant RNA Processing in a Neurodegenerative Disease: the Cause for Absent EAAT2, a Glutamate Transporter, in Amyotrophic Lateral Sclerosis , 1998, Neuron.

[7]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[8]  T. Deguchi,et al.  A null mutation in the human CNTF gene is not causally related to neurological diseases , 1994, Nature Genetics.

[9]  N. Hirokawa,et al.  Charcot-Marie-Tooth Disease Type 2A Caused by Mutation in a Microtubule Motor KIF1Bβ , 2001, Cell.

[10]  J. Hauw,et al.  The relationship between Bunina bodies, skein-like inclusions and neuronal loss in amyotrophic lateral sclerosis , 2002, Acta Neuropathologica.

[11]  H. Schild,et al.  Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. , 2001, Archives of neurology.

[12]  Marinos C. Dalakas,et al.  Muscle biopsy — a practical approach , 1986, The Ulster Medical Journal.

[13]  M W Weiner,et al.  Decreased N‐acetylaspartate in motor cortex and corticospinal tract in ALS , 1998, Neurology.

[14]  P. Andres,et al.  Quantitative assessment of neuromuscular deficit in ALS. , 1987, Neurologic clinics.

[15]  Volkmar Glauche,et al.  Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. , 2004, Brain : a journal of neurology.

[16]  Robert H. Brown,et al.  A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. , 2002, American journal of human genetics.

[17]  N. Hirokawa,et al.  Charcot-Marie-Tooth Disease Type 2A Caused by Mutation in a Microtubule Motor KIF1Bβ , 2001, Cell.

[18]  S H Appel,et al.  Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. , 1995, Brain : a journal of neurology.

[19]  W. Bradley,et al.  Amyotrophic lateral sclerosis: the search for a spectroscopic marker of upper motoneuron involvement. , 2001, Archives of neurology.

[20]  Mb Alan J. McComas Dr.,et al.  The extent and time course of motoneuron involvement in amyotrophic lateral sclerosis. , 1991 .

[21]  E. Sorenson Great Lakes ALS Study Group , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[22]  D. Shungu,et al.  Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. , 1999, Radiology.

[23]  F. Weber,et al.  Matrix metalloproteinase‐9 is elevated in serum of patients with amyotrophic lateral sclerosis , 2000, Neuroreport.

[24]  M. Bromberg,et al.  Sources of error in the spike‐triggered averaging method of motor unit number estimation (MUNE) , 1995, Muscle & nerve.

[25]  Jeffrey D. Rothstein,et al.  From charcot to lou gehrig: deciphering selective motor neuron death in als , 2001, Nature Reviews Neuroscience.

[26]  M. Pericak-Vance,et al.  Erratum: The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis (Nature Genetics (2001) 29 (160-165)) , 2001 .

[27]  A. Kakita,et al.  Neuropathology with Clinical Correlations of Sporadic Amyotrophic Lateral Sclerosis: 102 Autopsy Cases Examined Between 1962 and 2000 , 2003, Brain pathology.

[28]  J. Veldink,et al.  A randomized sequential trial of creatine in amyotrophic lateral sclerosis , 2003, Annals of neurology.

[29]  V. Meininger,et al.  Deletions causing spinal muscular atrophy do not predispose to amyotrophic lateral sclerosis. , 1999, Archives of neurology.

[30]  M. Beal,et al.  Increased oxidative damage to DNA in ALS patients. , 2000, Free radical biology & medicine.

[31]  A. Siderowf,et al.  Postural change of forced vital capacity predicts some respiratory symptoms in ALS , 2001, Neurology.

[32]  K. Mills,et al.  Magnetic brain stimulation: Central motor conduction studies in multiple sclerosis , 1987, Annals of neurology.

[33]  C. Armon,et al.  Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials 1 Presented in part at the 8th International Symposium on ALS/MND held in Glasgow, Scotland, November 3–5th, 1997. 1 , 1998, Journal of the Neurological Sciences.

[34]  E. Sorenson A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis , 2003, Neurology.

[35]  Orla Hardiman,et al.  Assessing individual quality of life in amyotrophic lateral sclerosis , 2004, Quality of Life Research.

[36]  R. Olney,et al.  Longitudinal study of fiber density and motor unit number estimate in patients with amyotrophic lateral sclerosis , 1997, Neurology.

[37]  P. F. Kauff Group , 2000, Elegant Design.

[38]  M. Tamaki,et al.  A loss of functional spinal alpha motor neurons in amyotrophic lateral sclerosis , 1998, Neurology.

[39]  J. Belleroche,et al.  Investigation of a null mutation of the CNTF gene in familial amyotrophic lateral sclerosis , 1995, Journal of the Neurological Sciences.

[40]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[41]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[42]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[43]  G. Parry,et al.  A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis , 1996 .

[44]  J. Coyle,et al.  Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis , 1990, Annals of neurology.

[45]  D. W. Mulder Clinical limits of amyotrophic lateral sclerosis. , 1982, Advances in neurology.

[46]  L. Krivickas,et al.  Amyotrophic lateral sclerosis and other motor neuron diseases. , 2003, Physical medicine and rehabilitation clinics of North America.

[47]  D. Arnold,et al.  Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. , 2003, AJNR. American journal of neuroradiology.

[48]  R K Olney,et al.  Comparison of multiple point and statistical motor unit number estimation , 2000, Muscle & nerve.

[49]  Hiroshi Tsukagoshi,et al.  Morphometric quantification of the cervical limb motor cells in controls and in amyotrophic lateral sclerosis , 1979, Journal of the Neurological Sciences.

[50]  M. Mattson,et al.  Presence of 4‐hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis , 1998, Annals of neurology.

[51]  Robert H. Brown,et al.  Decreased Metallation and Activity in Subsets of Mutant Superoxide Dismutases Associated with Familial Amyotrophic Lateral Sclerosis* 210 , 2002, The Journal of Biological Chemistry.

[52]  D. Clifford,et al.  Lamotrigine for HIV-associated painful sensory neuropathies , 2003, Neurology.

[53]  N. Gonatas,et al.  The Golgi apparatus is fragmented in spinal cord motor neurons of amyotrophic lateral sclerosis with basophilic inclusions , 2002, Acta Neuropathologica.

[54]  M. Swash,et al.  Clinical neurophysiology of ALS , 2001, Clinical Neurophysiology.

[55]  L. Haverkamp,et al.  Apolipoprotein E ɛ4 in bulbar-onset motor neuron disease , 1996, The Lancet.

[56]  S. Kato,et al.  Increased plasma TGF‐β1 in patients with amyotrophic lateral sclerosis , 2002, Acta neurologica Scandinavica.

[57]  G. Parry,et al.  Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis , 1996, Neurology.

[58]  W. Brown Thenar motor unit count estimates in the carpel tunnel syndrome , 1973, Journal of neurology, neurosurgery, and psychiatry.

[59]  E. Pioro Proton magnetic resonance spectroscopy ( 1 H-MRS) in ALS , 2000 .

[60]  A. Malafosse,et al.  Association between centromeric deletions of the SMN gene and sporadic adult‐onset lower motor neuron disease , 1998, Annals of neurology.

[61]  A. Pestronk,et al.  Distal lower motor neuron syndrome with high‐titer serum IgM anti‐GM1 antibodies , 1994, Neurology.

[62]  Hiroshi Mitsumoto,et al.  Diagnosis and progression of ALS , 1997, Neurology.

[63]  K. Toyka,et al.  Comparison of maximal voluntary isometric contraction and Drachman's hand‐held dynamometry in evaluating patients with amyotrophic lateral sclerosis , 1999, Muscle & nerve.

[64]  C. Elger,et al.  Effect of Creatine Supplementation on Metabolite Levels in ALS Motor Cortices , 2001, Experimental Neurology.

[65]  C. Wessig,et al.  Creatine monohydrate in DM2/PROMM , 2003, Neurology.

[66]  Shin J. Oh,et al.  Mutant dynactin in motor neuron disease , 2003, Nature Genetics.

[67]  P. Andres,et al.  Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis , 1988, Neurology.

[68]  W. Brown,et al.  Changes in motor unit populations in motor neurone disease. , 1979, Journal of neurology, neurosurgery, and psychiatry.

[69]  F. H. Tyler,et al.  Assessment of muscle strength in Duchenne muscular dystrophy , 1977, Neurology.

[70]  Clifton L Gooch,et al.  Motor unit number estimation. , 2003, Physical medicine and rehabilitation clinics of North America.

[71]  Mark B. Bromberg,et al.  Relationships between motor-unit number estimates and isometric strength in distal muscles in ALS/MND , 1996, Journal of the Neurological Sciences.

[72]  S. Hansen,et al.  A quantitative electrophysiological study of motor neurone disease. , 1978, Journal of neurology, neurosurgery, and psychiatry.

[73]  Robert H. Brown,et al.  Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis , 2003, Annals of neurology.

[74]  T. Munsat,et al.  Recombinant growth hormone treatment of amyotrophic lateral sclerosis , 1993, Muscle & nerve.

[75]  Robert H. Brown,et al.  Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis , 1997, Annals of neurology.

[76]  N. Schuff,et al.  Early detection and longitudinal changes in amyotrophic lateral sclerosis by 1H MRSI , 2002 .

[77]  M. Pericak-Vance,et al.  The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis , 2001, Nature Genetics.

[78]  M J Campbell,et al.  Electrophysiological estimation of the number of motor units within a human muscle , 1971, Journal of neurology, neurosurgery, and psychiatry.

[79]  T L Munsat,et al.  Quantitative motor assessment in amyotrophic lateral sclerosis , 1986, Neurology.

[80]  Robert H. Brown,et al.  Apolipoprotein E ϵ4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis , 1995 .

[81]  P. Sham,et al.  Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. , 1996, Lancet.

[82]  J. Powell,et al.  Association of apolipoprotein E ∈4 allele with bulbar-onset motor neuron disease , 1996, The Lancet.

[83]  T J Doherty,et al.  Determinants of mean motor unit size: Impact on estimates of motor unit number , 1993, Muscle & nerve.

[84]  M. Billiard,et al.  Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis , 1993, Acta neurologica Scandinavica.

[85]  D. Arnold,et al.  Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo , 1994, Neurology.

[86]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[87]  K. Mills,et al.  Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis , 1997, Muscle & nerve.

[88]  L. F. Black,et al.  Maximal respiratory pressures: normal values and relationship to age and sex. , 2015 .

[89]  M. Naumann,et al.  Disease progression in amyotrophic lateral sclerosis: Predictors of survival , 2002, Muscle & nerve.

[90]  A. Pestronk,et al.  Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation , 1994, Annals of neurology.

[91]  J. Engstrom,et al.  Statistical motor unit number estimation: Reproducibility and sources of error in patients with amyotrophic lateral sclerosis , 2000, Muscle & nerve.

[92]  M. Brandstater,et al.  Motor unit number estimate–based rates of progression of ALS predict patient survival , 1999, Muscle & nerve.

[93]  D. Arnold,et al.  A prospective, randomized, placebo‐controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[94]  P. Urban,et al.  Sensitivity of transcranial magnetic stimulation of cortico-bulbar vs. cortico-spinal tract involvement in Amyotrophic Lateral Sclerosis (ALS) , 2001, Journal of Neurology.

[95]  M. Polkey,et al.  Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. , 2001, Brain : a journal of neurology.

[96]  J. Shefner,et al.  Reducing intersubject variability in motor unit number estimation , 1999, Muscle & nerve.

[97]  J. Cedarbaum,et al.  Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials , 1997, Journal of the Neurological Sciences.

[98]  A. McComas,et al.  The extent and time course of motoneuron involvement in amyotrophic lateral sclerosis , 1991, Muscle and Nerve.

[99]  Jeremy M. Shefner,et al.  Motor unit number estimation in human neurological diseases and animal models , 2001, Clinical Neurophysiology.

[100]  A. McComas,et al.  Motor unit populations in healthy and diseased muscles. , 1993, Physical therapy.

[101]  K. Roemer,et al.  High rate of constitutional chromosomal rearrangements in apparently sporadic ALS , 2003, Neurology.

[102]  P. Andres,et al.  The natural history of motoneuron loss in amyotrophic lateral sclerosis , 1988, Neurology.

[103]  J. Shefner,et al.  Motor unit number estimation in neurologic disease. , 2002, Advances in neurology.

[104]  K. Okamoto,et al.  Reduction of the size of the Golgi apparatus of spinal anterior horn cells in patients with X‐linked spinal and bulbar muscular atrophy , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[105]  H. Thoenen,et al.  Disruption of the CNTF gene results in motor neuron degeneration , 1993, Nature.

[106]  M. Province,et al.  Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures. , 1984, Physical therapy.

[107]  G. Parry,et al.  Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis , 2001, Neurology.

[108]  L. Rowland Diagnosis of amyotrophic lateral sclerosis , 1998, Journal of the Neurological Sciences.

[109]  M. Bromberg,et al.  Motor unit number estimation, isometric strength, and electromyographic measures in amyotrophic lateral sclerosis , 1993, Muscle & nerve.

[110]  Markus Weber,et al.  Assessment of upper and lower motor neurons in Kennedy's disease: Implications for corticomotoneuronal PSTH studies , 1999, Muscle & nerve.

[111]  T. Deguchi,et al.  Erratum: A null mutation in the human CNTF gene is not causally related to neurological diseases , 1994, Nature Genetics.

[112]  J. Cedarbaum,et al.  Prognostic indicators of survival in ALS , 1998, Neurology.

[113]  The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. , 1996, Archives of neurology.

[114]  M. Iwata,et al.  Ultrastructural study of Betz cells in the primary motor cortex of the human brain , 2001, Journal of anatomy.

[115]  C. Andres,et al.  Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis , 2002, Annals of neurology.

[116]  T. Pabst,et al.  1H Spectroscopy in Patients With Amyotrophic Lateral Sclerosis , 2001, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[117]  Jm Charcot,et al.  Deux cas d’atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antero-lateraux de la moelle epiniere , 1869 .

[118]  D. Cleveland,et al.  Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[119]  M. Mimura,et al.  Constant involvement of the Betz cells and pyramidal tract in amyotrophic lateral sclerosis with dementia: a clinicopathological study of eight autopsy cases , 2002, Acta Neuropathologica.

[120]  D. Borchelt,et al.  Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[121]  D. Schoenfeld,et al.  A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis , 2003, Neurology.

[122]  R. Sufit,et al.  Design of clinical therapeutic trials in amyotrophic lateral sclerosis. , 1991, Advances in neurology.

[123]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[124]  Michael Swash,et al.  Early diagnosis of ALS/MND , 1998, Journal of the Neurological Sciences.

[125]  Mulder Dw Clinical limits of amyotrophic lateral sclerosis. , 1982 .

[126]  L. Rowland Human motor neuron diseases. , 1982, Advances in neurology.

[127]  W. Paulus,et al.  Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis , 1997, Neurology.

[128]  P M Pattany,et al.  MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. , 2000, AJNR. American journal of neuroradiology.

[129]  J. Petajan,et al.  Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis , 1997, Muscle & nerve.

[130]  G. Smith,et al.  A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience , 1987, Annals of neurology.

[131]  C. Armon,et al.  Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis , 2000, Muscle & nerve.

[132]  B. Crain,et al.  Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. , 1998, American journal of human genetics.

[133]  K J Felice,et al.  A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis , 1997, Muscle & nerve.

[134]  Clifton L Gooch Motor Unit Number Estimation: Pro , 2002, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[135]  W F Brown,et al.  A method for estimating the number of motor units in thenar muscles and the changes in motor unit count with ageing , 1972, Journal of neurology, neurosurgery, and psychiatry.

[136]  A. Malafosse,et al.  Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis , 1996, Journal of the Neurological Sciences.

[137]  T. Ng,et al.  1H-MRS evidence of neurodegeneration and excess glutamate glutamine in ALS medulla , 1999, Neurology.

[138]  A. Al-Chalabi,et al.  Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: Homozygous naip deletion in a sporadic case , 1996, Annals of neurology.

[139]  A. McComas,et al.  Early and late losses of motor units after poliomyelitis. , 1997, Brain : a journal of neurology.